You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Scottish bioinformatics firm will crunch multi-omic datasets to assist Charles River Laboratories in "data-driven" drug discovery.
Mayo Clinic Ventures and NTT Venture Capital have invested in the AI software developer to synthesize biomedical data for drug development and precision medicine.
The new system, called BODE 2, will launch at the end of this year and will replace the existing BODE for the analysis of "big omics" data for research.
Analyzing patient exome sequence data, investigators identified germline variants with apparent ties to estrogen receptor-positive breast cancer recurrence.
The "augmented intelligence" startup applies machine learning and contextual language processing to make sense of multi-omics datasets and inform drug discovery.
WUSTL spinout PercayAI will provide augmented intelligence technology to Canopy Biosciences' RNA-seq and NanoString tests to inform drug discovery.
Hatched from the computational genomics lab at Ghent University, BioLizard offers a small but complementary team to tackle AI and molecular pipeline challenges.
The anonymous gift, to be made in annual installments over 10 years, will support interdisciplinary work at the campus's Genomics Institute headquarters.
Researchers focused on using existing computational methods to fill in gaps in the human microbiome without reference genomes.
A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.
Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.
The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.
In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.